NFKB1 and asthma: A further study revealed that miR-223 can regulate the expression of mucin 5 AC (MUC5AC), eotaxin-2 (CCL24) and thymic stromal lymphopoietin (TSLP) by targeting NF-kB signaling pathway, this suggests that miR-223 is a regulator of allergic inflammation and could potentially consider as novel and targeted therapy for asthma (117) (Figure 4).